[#item_full_content]CARY, N.C.–(BUSINESS WIRE)–Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products today announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003). ACT-IOP-003 is a novel implanted precision therapeutic system intended to safely deliver multiple doses of gemcitabine (an FDA approved therapeutic agent) locally and actively